Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBITDA (2021 - 2025)

Historic EBITDA for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $79.3 million.

  • Krystal Biotech's EBITDA rose 17043.58% to $79.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.5 million, marking a year-over-year increase of 26578.7%. This contributed to the annual value of $88.3 million for FY2024, which is 61825.5% up from last year.
  • As of Q3 2025, Krystal Biotech's EBITDA stood at $79.3 million, which was up 17043.58% from $39.1 million recorded in Q2 2025.
  • Krystal Biotech's EBITDA's 5-year high stood at $80.6 million during Q3 2023, with a 5-year trough of -$51.0 million in Q1 2022.
  • Moreover, its 5-year median value for EBITDA was -$15.6 million (2021), whereas its average is $2.4 million.
  • As far as peak fluctuations go, Krystal Biotech's EBITDA crashed by 22247.23% in 2022, and later skyrocketed by 72636000.0% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's EBITDA stood at -$22.0 million in 2021, then crashed by 42.59% to -$31.3 million in 2022, then skyrocketed by 131.02% to $9.7 million in 2023, then soared by 350.75% to $43.8 million in 2024, then surged by 81.16% to $79.3 million in 2025.
  • Its last three reported values are $79.3 million in Q3 2025, $39.1 million for Q2 2025, and $36.3 million during Q1 2025.